Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2

✍ Scribed by Jennifer Snaddon; Matthew L. Smith; Michael Neat; Maxine Cambal-Parrales; Amanda Dixon-McIver; Rachael Arch; John A. Amess; Ama Z. Rohatiner; T. Andrew Lister; Jude Fitzgibbon

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 445 KB
• Volume: 37
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/gcc.10185

✦ Synopsis

CEBPA encodes the transcription factor C/EBPalpha and is specifically up-regulated during granulocytic differentiation. The gene is mutated in approximately 20% of patients with acute myeloid leukemia (AML) FAB type M2 and occurs in the absence of the t(8;21). In much the same way as specific translocations are associated with a particular AML FAB type, the identification of non-random associations of gene mutation with karyotype or FAB type may be helpful in elucidating the molecular basis of certain forms of leukemia. To confirm these initial findings, 99 patients with AML FAB type M1 or M2 were screened for CEBPA mutations by use of a PCR-single-strand conformational polymorphism and sequencing approach. Nine CEBPA mutations were identified in eight patients. The mutations were clustered toward the COOH terminal of the protein and occurred exclusively in the intermediate cytogenetic risk group (8/64, 12.5%). Two patients with biallelic mutation, one homozygous for 1137Ins (57 bp) and another with two CEBPA mutations, 1096Ins (27 bp) and 363Ins (GGCC), were observed. There was no evidence for deletion of this region in the other six mutated samples analyzed by fluorescence in situ hybridization with a BAC clone spanning the CEBPA locus. CEBPA mutation status was not demonstrated to be of prognostic importance in this patient group, although this may reflect the selection and size of the AML population studied. In conclusion, mutation of CEBPA is a recurrent finding in AML and appears specific to the intermediate cytogenetic risk group patients.